OLMA Olema Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OLMA

Price (delayed)

$10.15

Market cap

$567.53M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.14

Enterprise value

$501.41M

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is ...

Highlights
OLMA's EPS is up by 18% YoY and by 8% QoQ
The debt has declined by 8% since the previous quarter and by 6% year-on-year
Olema Pharmaceuticals's equity has increased by 29% YoY but it has decreased by 8% from the previous quarter
OLMA's quick ratio is down by 30% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.olemapharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of OLMA
Market
Shares outstanding
55.91M
Market cap
$567.53M
Enterprise value
$501.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$96.66M
EBITDA
-$94.98M
Free cash flow
-$83.71M
Per share
EPS
-$2.14
Free cash flow per share
-$1.85
Book value per share
$4.64
Revenue per share
$0
TBVPS
$6.12
Balance sheet
Total assets
$276.95M
Total liabilities
$23.05M
Debt
$2.42M
Equity
$253.9M
Working capital
$244.89M
Liquidity
Debt to equity
0.01
Current ratio
12.33
Quick ratio
12.11
Net debt/EBITDA
0.7
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-41%
Return on equity
-44.7%
Return on invested capital
-62.5%
Return on capital employed
-37.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OLMA stock price

How has the Olema Pharmaceuticals stock price performed over time
Intraday
1.5%
1 week
-5.23%
1 month
-9.62%
1 year
151.24%
YTD
-27.66%
QTD
-10.34%

Financial performance

How have Olema Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$104.96M
Net income
-$96.66M
Gross margin
N/A
Net margin
N/A
Olema Pharmaceuticals's net income has increased by 8% YoY
The operating income has decreased by 3.1% QoQ

Growth

What is Olema Pharmaceuticals's growth rate over time

Valuation

What is Olema Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OLMA's EPS is up by 18% YoY and by 8% QoQ
Olema Pharmaceuticals's equity has increased by 29% YoY but it has decreased by 8% from the previous quarter
OLMA's price to book (P/B) is 10% more than its last 4 quarters average of 2.0

Efficiency

How efficient is Olema Pharmaceuticals business performance
The return on invested capital has declined by 25% year-on-year
Olema Pharmaceuticals's ROE has increased by 6% from the previous quarter and by 2.2% YoY
The return on assets has grown by 6% since the previous quarter and by 4.7% year-on-year

Dividends

What is OLMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OLMA.

Financial health

How did Olema Pharmaceuticals financials performed over time
OLMA's current ratio is down by 30% since the previous quarter and by 2.3% year-on-year
OLMA's quick ratio is down by 30% since the previous quarter
The debt is 99% smaller than the equity
Olema Pharmaceuticals's equity has increased by 29% YoY but it has decreased by 8% from the previous quarter
The debt has declined by 8% since the previous quarter and by 6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.